WallStSmart

Accendra Health Inc (ACH)vsPfizer Inc (PFE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Pfizer Inc generates 2192% more annual revenue ($63.32B vs $2.76B). PFE leads profitability with a 11.8% profit margin vs -39.9%. ACH appears more attractively valued with a PEG of 0.70. PFE earns a higher WallStSmart Score of 55/100 (C).

ACH

Hold

48

out of 100

Grade: D+

Growth: 2.7Profit: 3.0Value: 6.0Quality: 5.0

PFE

Buy

55

out of 100

Grade: C

Growth: 3.3Profit: 7.0Value: 5.3Quality: 4.8
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for ACH.

PFEUndervalued (+29.4%)

Margin of Safety

+29.4%

Fair Value

$37.48

Current Price

$25.68

$11.80 discount

UndervaluedFair: $37.48Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ACH1 strengths · Avg: 8.0/10
PEG RatioValuation
0.708/10

Growing faster than its price suggests

PFE4 strengths · Avg: 8.8/10
Operating MarginProfitability
31.6%10/10

Strong operational efficiency at 31.6%

Market CapQuality
$150.92B9/10

Large-cap with strong market position

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$2.18B8/10

Generating 2.2B in free cash flow

Areas to Watch

ACH4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$285.88M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
2.9%3/10

Operating margin of 2.9%

Return on EquityProfitability
-163.8%2/10

ROE of -163.8% — below average capital efficiency

PFE3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
13.772/10

Expensive relative to growth rate

EPS GrowthGrowth
-10.1%2/10

Earnings declined 10.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : ACH

The strongest argument for ACH centers on PEG Ratio. PEG of 0.70 suggests the stock is reasonably priced for its growth.

Bull Case : PFE

The strongest argument for PFE centers on Operating Margin, Market Cap, Price/Book.

Bear Case : ACH

The primary concerns for ACH are EPS Growth, Market Cap, Operating Margin.

Bear Case : PFE

The primary concerns for PFE are Piotroski F-Score, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

ACH profiles as a turnaround stock while PFE is a value play — different risk/reward profiles.

ACH carries more volatility with a beta of 1.70 — expect wider price swings.

PFE is growing revenue faster at 5.4% — sustainability is the question.

PFE generates stronger free cash flow (2.2B), providing more financial flexibility.

Bottom Line

PFE scores higher overall (55/100 vs 48/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Accendra Health Inc

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Aluminum Corporation of China Limited, manufactures and sells alumina, primary aluminum and energy products in the People's Republic of China. The company is headquartered in Beijing, the People's Republic of China.

Pfizer Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Visit Website →

Want to dig deeper into these stocks?